Biosynthesis and engineering of isoprenoid small molecules
Isoprenoid secondary metabolites are a rich source of commercial products that have not been fully explored. At present, there are isoprenoid products used in cancer therapy, the treatment of infectious diseases, and crop protection. All isoprenoids share universal prenyl diphosphate precursors synthesized via two distinct pathways. From these universal precursors, the biosynthetic pathways to specific isoprenoids diverge resulting in a staggering array of products. Taking advantage of this diversity has been the focus of much effort in metabolic engineering heterologous hosts. In addition, the engineering of the mevalonate pathway has increased levels of the universal precursors available for heterologous production. Finally, we will describe the efforts to produce to commercial terpenoids, paclitaxel and artemisinin.
KeywordsIsoprenoids Terpenes Synthetic biology Metabolic engineering Artemisinin
- Dictionary of natural products (2004) Version 8.1 (HRD), 1st edn. Chapman & Hall, London, UKGoogle Scholar
- Steele CL, Crock J et al (1998a) Sesquiterpene synthases from grand fir (Abies grandis). Comparison of constitutive and wound-induced activities, and cDNA isolation, characterization, and bacterial expression of delta-selinene synthase and gamma-humulene synthase. J Biol Chem 273:2078–2089PubMedCrossRefGoogle Scholar
- Szkopinska A, Swiezewska E et al (2000) The regulation of activity of main mevalonic acid pathway enzymes: farnesyl diphosphate synthase, 3-hydroxy-3-methylglutaryl-CoA reductase, and squalene synthase in yeast Saccharomyces cerevisiae. Biochem Biophys Res Commun 267:473–477PubMedCrossRefGoogle Scholar